Abstract
Anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies were first described in 2009 and implicated in the pathogenesis of idiopathic membranous nephritis (IMN). This was a significant advance given that until then, the pathogenesis of IMN was unclear and differentiation from secondary membranous nephritis could be challenging. Since this initial study describing the anti-PLA2R antibody, several other investigators have confirmed the association of this autoantibody with IMN. Furthermore, anti-PLA2R antibodies correlate with clinical outcomes and can be used to measure response to treatment. Therefore, anti-PLA2R autoantibodies have promising applications to the diagnosis, monitoring, and treatment of IMN.
| Original language | English (US) |
|---|---|
| Title of host publication | Autoantibodies |
| Subtitle of host publication | Third Edition |
| Publisher | Elsevier B.V. |
| Pages | 545-552 |
| Number of pages | 8 |
| ISBN (Print) | 9780444563781 |
| DOIs | |
| State | Published - Dec 2013 |
Keywords
- Anti-phospholipase A2 receptor antibodies
- Lupus nephritis
- Membranous nephropathy
- Phospholipase A2 receptor
- Podocytes
- Systemic lupus erythematosus
ASJC Scopus subject areas
- General Immunology and Microbiology